Global markets have recently experienced a series of gains, with major indices such as the Dow Jones Industrial Average and S&P 500 Index reaching record intraday highs, despite geopolitical tensions and domestic policy shifts influencing investor sentiment. Amid these developments, the concept of penny stocks—often associated with smaller or newer companies—continues to capture interest due to their affordability and potential for growth. While the term may seem outdated, these stocks can offer intriguing opportunities when backed by strong financials.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
DXN Holdings Bhd (KLSE:DXN) |
MYR0.485 |
MYR2.41B |
★★★★★★ |
|
Embark Early Education (ASX:EVO) |
A$0.79 |
A$146.79M |
★★★★☆☆ |
|
Datasonic Group Berhad (KLSE:DSONIC) |
MYR0.40 |
MYR1.11B |
★★★★★★ |
|
Hil Industries Berhad (KLSE:HIL) |
MYR0.875 |
MYR290.45M |
★★★★★★ |
|
ME Group International (LSE:MEGP) |
£2.19 |
£825.11M |
★★★★★★ |
|
Bosideng International Holdings (SEHK:3998) |
HK$4.05 |
HK$44.6B |
★★★★★★ |
|
LaserBond (ASX:LBL) |
A$0.565 |
A$64.47M |
★★★★★★ |
|
Lever Style (SEHK:1346) |
HK$0.86 |
HK$545.92M |
★★★★★★ |
|
Next 15 Group (AIM:NFG) |
£4.275 |
£425.17M |
★★★★☆☆ |
|
Secure Trust Bank (LSE:STB) |
£3.69 |
£70.37M |
★★★★☆☆ |
Click here to see the full list of 5,702 stocks from our Penny Stocks screener.
Let’s review some notable picks from our screened stocks.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Viva Biotech Holdings is an investment holding company that provides structure-based drug discovery services to biotechnology and pharmaceutical clients globally, with a market cap of HK$1.91 billion.
Operations: The company’s revenue is derived from Drug Discovery Services, which generated CN¥780.09 million, and Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥1.21 billion.
Market Cap: HK$1.91B
Viva Biotech Holdings, with a market cap of HK$1.91 billion, faces challenges due to its unprofitability and increased debt-to-equity ratio over five years. Its short-term assets of CN¥1.9 billion exceed liabilities, but long-term liabilities remain uncovered. Despite losses growing at 23.5% annually over the past five years, the company maintains a cash runway exceeding three years due to positive free cash flow growth of 22.3%. Recent strategic moves include share buybacks aimed at enhancing net asset value per share and earnings per share, funded by internal resources amidst executive changes in financial leadership roles.
